參考文獻(xiàn)/References:
[1] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] 龔曉斌, 劉詩怡, 夏天一,等.阿帕替尼在惡性腫瘤治療中的臨床應(yīng)用與研究進(jìn)展[J]. 藥學(xué)實(shí)踐雜志, 2018, 36(2): 103-107,130.
[3] 張凱戀, 褚倩, 陳元.非小細(xì)胞肺癌抗血管生成藥物治療進(jìn)展[J]. 醫(yī)藥導(dǎo)報(bào), 2018, 37(5): 546-550.
[4] Sandler A, Gray R, Perry M C, et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006, 355(24): 2542-2550.
[5] Reck M, Kaiser R, MellemgaardA, et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer(LUME-Lung 1): a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15(2): 143-155.
[6] Sequist L V, Yang J C, Yamamoto N, et al.Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013, 31(27): 3327-3334.
[7] Peng S,Zhang Y,Peng H, et al.Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib[J].Cancer Lett,2016,373(2):193-202.
[8] Di Maio M,Chiodini P,Georgoulias V, et al.Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol, 2009,27(11):1836-1843.
[9] 張力, 李凱, 史美祺,等.甲磺酸阿帕替尼治療晚期非鱗非小細(xì)胞肺癌隨機(jī)、雙盲、安慰劑對照、多中心Ⅱ期臨床研究[C].北京:第十五屆全國臨床腫瘤學(xué)大會(huì)暨2012年CSCO學(xué)術(shù)年會(huì)論文集, 2012: 24-24.
[10] Planchard D, Le Pechoux C.Small cell lung cancer: new clinical recommendations and current status of biomarker assessment[J]. Eur J Cancer, 2011, 47(Suppl 3): S272-283.
[11] 邵為朋,王曉偉,劉德若.小細(xì)胞肺癌目前治療的策略與未來方向[J].中國肺癌雜志,2017,20(6):421-426.
[12] 王文嫻,張沂平.小細(xì)胞肺癌的靶向治療[J].國際腫瘤學(xué)雜志,2015(6):452-454.
[13] Spigel D R, Townley P M, Waterhouse D M, et al.Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial[J]. J Clin Oncol, 2011, 29(16): 2215-2222.
[14] 李春杏,高玲燕,鄭麗,等.阿帕替尼對晚期實(shí)體惡性腫瘤療效和安全性Meta分析[J].中華腫瘤防治雜志,2018,25(15):1113-1122.